|
|
|
| Effects of Ultra-early Application of Alteplase Intravenous Thrombolysis on Clinical Outcomes of Patients with Cerebral Infarction |
| WANG He, SUN Yuanlin |
| Panjin Central Hospital, Liaoning Panjin 124010, China |
|
|
|
|
Abstract Objective: To explore the clinical effects of ultra-early application of alteplase intravenous thrombolysis on cerebral infarction and its influence on clinical outcomes. Methods: From January 2017 to January 2019, 96 patients with cerebral infarction in our hospital were selected. According to different treatment methods, they were divided into control group and study group, 48 cases in each group. Control group was given combined treatment of Bayaspirin enteric-coated tablets, clopidogrel hydrogen sulphate tablets and Shuxuetong injection while study group was given ultra-early application of alteplase intravenous thrombolysis, and given routine administration of Bayaspirin enteric-coated tablets and clopidogrel hydrogen sulphate tablet after 24hs, and method and dose in study group were the same as control group, and they were treated for 2 weeks. The neurological deficit, daily living ability, inflammatory factors levels, central nervous system-specific protein level, neuro-specific enolase level, coagulation function and adverse reactions after administration were compared between the two groups. Results: There were no adverse reactions in study group, and there was no significant difference compared with 2.08% in control group (P>0.05). The neurological deficit score, Barthel index score, S100β level, NSE level and various inflammatory factors in the two groups were effectively improved after treatment, and the improvements in study group were better than those in control group (P<0.05). After treatment, the plasma fibrinogen FIB of the two groups was significantly decreased (P<0.05). However, there were no significant differences in the coagulation function indexes between the two groups (P<0.05). Conclusion: Ultra-early alteplase intravenous thrombolysis has reliable effects and good safety in the treatment of patients with cerebral infarction, thus it is worthy of promotion.
|
|
|
|
|
|
[1] 黄文胜,梁华忠.急性脑梗死溶栓治疗研究进展[J].内科,2019,14(1):56~58,64.
[2] 王艳竹.阿替普酶静脉溶栓联合丁苯酞治疗超早期脑梗死的临床疗效评价[J].中国处方药,2018,16(5):69.
[3] 谢硬.关于CT影像和MRI检查在老年多发性脑梗死诊断中的运用分析[J].影像研究与医学应用,2019,3(7):44~45.
[4] 孔令胜.影响急性脑梗死静脉rt-PA溶栓早期疗效的相关因素分析[J].世界复合医学,2019,5(1):85-86,120.
[5] 李振环,张斌.超早期急性脑梗死应用阿替普酶急诊静脉溶栓治疗的临床研究[J].世界最新医学信息文摘,2016,16(65):79~80.
[6] 王勤鹰,詹青.急性脑梗死重组组织型纤溶酶原激活物静脉溶栓后严重出血性转化研究进展[J].神经病学与神经康复学杂志,2017,13(1):25~31.
[7] 谢江文,吕国菊,郑珍婕,等.不同年龄对阿替普酶静脉溶栓治疗急性脑梗死的临床疗效和预后的影响[J].中国临床药理学杂志,2016,32(6):486~488.
[8] 陈伦任.静脉溶栓中不同剂量阿替普酶的应用对急性缺血性脑卒中的治疗效果[J].实用医技杂志,2019,26(7):861~862.
[9] 蒋玉兰,王相明.银杏叶片阿司匹林肠溶片及阿托伐他汀钙片联用对脑梗死恢复期患者的临床疗效[J].安徽医学,2018,39(2):178~181. |
|
|
|
2020, Vol. 26 
